MedTrace Logo

Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients

NCT02998931 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-10-16

No results posted yet for this study

Summary

Glutamine supplementation has beneficial effects on morbidity and mortality in critically ill patients, possibly in part through an attenuation of the proinflammatory cytokine response and a Immune function. In this trial intensive care unit patients with enteral feeding will receive either enteral glutamine or maltodextrin as placebo for 28 days.

Conditions

  • Critical Illness
  • Enteral Nutrition
  • Multiple Organ Failure
  • Infection Complication
  • Inflammation

Interventions

DRUG

Glutamin

Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs

OTHER

Maltodextrin

Maltodextrin mixed with water given via NG tube Q 4 hours

Sponsors & Collaborators

  • Shahid Beheshti University

    lead OTHER

Principal Investigators

  • Zahra Vahdat Shariatpanahi, MD, PhD · Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-10
Primary Completion
2018-08-25
Completion
2018-09-10

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02998931 on ClinicalTrials.gov